AU2020346456A1 - TAK-925 for use in treating narcolepsy - Google Patents
TAK-925 for use in treating narcolepsy Download PDFInfo
- Publication number
- AU2020346456A1 AU2020346456A1 AU2020346456A AU2020346456A AU2020346456A1 AU 2020346456 A1 AU2020346456 A1 AU 2020346456A1 AU 2020346456 A AU2020346456 A AU 2020346456A AU 2020346456 A AU2020346456 A AU 2020346456A AU 2020346456 A1 AU2020346456 A1 AU 2020346456A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subject
- methyl
- administration
- plasma concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900298P | 2019-09-13 | 2019-09-13 | |
| US62/900,298 | 2019-09-13 | ||
| US202063031686P | 2020-05-29 | 2020-05-29 | |
| US63/031,686 | 2020-05-29 | ||
| PCT/IB2020/058483 WO2021048822A1 (en) | 2019-09-13 | 2020-09-12 | Tak-925 for use in treating narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020346456A1 true AU2020346456A1 (en) | 2022-04-14 |
Family
ID=72560858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020346456A Abandoned AU2020346456A1 (en) | 2019-09-13 | 2020-09-12 | TAK-925 for use in treating narcolepsy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220339143A1 (https=) |
| EP (1) | EP4028004A1 (https=) |
| JP (1) | JP2022547711A (https=) |
| KR (1) | KR20220062012A (https=) |
| CN (1) | CN114980892A (https=) |
| AU (1) | AU2020346456A1 (https=) |
| BR (1) | BR112022004587A2 (https=) |
| CA (1) | CA3154321A1 (https=) |
| CO (1) | CO2022004596A2 (https=) |
| MX (1) | MX2022003018A (https=) |
| WO (1) | WO2021048822A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022004576A2 (pt) * | 2019-09-13 | 2022-06-14 | Takeda Pharmaceuticals Co | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica |
| MX2022008392A (es) | 2020-01-10 | 2022-08-08 | Takeda Pharmaceuticals Co | Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| BR112023020104A2 (pt) * | 2021-04-02 | 2023-11-14 | Takeda Pharmaceuticals Co | Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides |
| CN119677753A (zh) | 2022-04-22 | 2025-03-21 | 帝人制药株式会社 | 氧杂氮杂环庚三烯衍生物 |
| AR130709A1 (es) | 2022-10-07 | 2025-01-08 | Kissei Pharmaceutical | Compuesto de ciclopentano |
| WO2024095158A1 (en) * | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| TW202535890A (zh) | 2023-10-20 | 2025-09-16 | 日商帝人製藥股份有限公司 | 氧氮呯衍生物之結晶或其溶劑合物之結晶 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025229493A1 (en) * | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| ES2843952T3 (es) * | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
| US10022355B2 (en) * | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
-
2020
- 2020-09-12 CA CA3154321A patent/CA3154321A1/en active Pending
- 2020-09-12 JP JP2022516270A patent/JP2022547711A/ja active Pending
- 2020-09-12 WO PCT/IB2020/058483 patent/WO2021048822A1/en not_active Ceased
- 2020-09-12 CN CN202080073637.7A patent/CN114980892A/zh active Pending
- 2020-09-12 BR BR112022004587A patent/BR112022004587A2/pt unknown
- 2020-09-12 AU AU2020346456A patent/AU2020346456A1/en not_active Abandoned
- 2020-09-12 KR KR1020227011013A patent/KR20220062012A/ko active Pending
- 2020-09-12 EP EP20775077.9A patent/EP4028004A1/en not_active Withdrawn
- 2020-09-12 MX MX2022003018A patent/MX2022003018A/es unknown
- 2020-09-12 US US17/642,331 patent/US20220339143A1/en not_active Abandoned
-
2022
- 2022-04-11 CO CONC2022/0004596A patent/CO2022004596A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022004587A2 (pt) | 2022-06-14 |
| KR20220062012A (ko) | 2022-05-13 |
| CN114980892A (zh) | 2022-08-30 |
| US20220339143A1 (en) | 2022-10-27 |
| WO2021048822A1 (en) | 2021-03-18 |
| CO2022004596A2 (es) | 2022-08-30 |
| CA3154321A1 (en) | 2021-03-18 |
| EP4028004A1 (en) | 2022-07-20 |
| MX2022003018A (es) | 2022-06-14 |
| JP2022547711A (ja) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020346456A1 (en) | TAK-925 for use in treating narcolepsy | |
| US20220331303A1 (en) | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness | |
| TWI298254B (en) | Use of optically pure (s,s) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome | |
| US12594269B2 (en) | Method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450 | |
| EP4611745A1 (en) | Dosing of orexin type 2 receptor agonists | |
| JP2015509931A (ja) | 医薬的な組み合わせ | |
| Napoliello et al. | Buspirone: a worldwide update | |
| JP7607864B2 (ja) | Ｋｖ７チャネル活性化剤の使用方法 | |
| AU2022252108A1 (en) | Use of an orexin 2 receptor agonist for post operation recovery | |
| WO2022190060A1 (en) | An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder | |
| WO2007088473A2 (en) | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain | |
| JP2008514689A (ja) | Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用 | |
| HK40113570A (en) | Methods of use for kv7 channel activators | |
| CA3270681A1 (en) | Dosing of orexin type 2 receptor agonists | |
| JP2010513227A (ja) | 覚醒を促進するためのＩｈチャネル阻害剤 | |
| Kompoliti et al. | Non‐Parkinsonian Movement Disorders | |
| HK40000275B (en) | Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |